iBio, Inc. (IBIO) has priced an underwritten public offering of pre-funded warrants for 71.54 million shares, raising $50 million in gross proceeds at $0.699 per share. The offering includes Series G and Series H warrants with an exercise price of $0.70 per share. If fully exercised in cash, the warrants could generate an additional $50 million. Proceeds will be used to advance iBio’s preclinical cardiometabolic programs and support working capital needs. The offering is being made under iBio’s effective shelf registration on Form S-3 via prospectus supplement and base prospectus filed with the SEC. IBIO currently trades at $0.7329 on the NasdaqCM.

Read more at Nasdaq: IBio Prices $50 Mln Public Offering To Advance Preclinical Antibody Programs